Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio, Inc. (symbol: GRI) is a pioneering clinical-stage biotech company dedicated to fundamentally transforming the treatment of inflammatory diseases. Specializing in the innovative development of therapies targeting dysregulated immune responses, GRI Bio focuses on inflammatory, fibrotic, and autoimmune disorders.
The company's core technology revolves around Natural Killer T (NKT) cell-based therapies. NKT cells are unique as they possess characteristics of both NK and T cells, serving as a critical bridge between innate and adaptive immune responses. Notably, Type 1 NKT cells are instrumental in initiating and propagating inflammatory responses and mediate the hepatic injury observed in liver diseases.
GRI Bio's lead program, GRI-0621, is an orally administered small molecule that acts as an inhibitor of Type 1 NKT cells. This groundbreaking therapy is being developed for the treatment of acute liver failure, aiming to curb hepatic inflammation by restoring immune system balance. Additionally, GRI-0621 serves as a RAR-beta and gamma dual agonist, further enhancing its therapeutic potential.
In addition to GRI-0621, the company boasts other promising candidates including GRI-0803, a novel oral agonist targeting Type 2 NKT cells. This candidate holds significant promise as a potential treatment for autoimmune disorders, further broadening GRI Bio's therapeutic arsenal.
GRI Bio's dedication to innovation and commitment to addressing unmet medical needs position it as a significant player in the biotech industry. With ongoing advancements and a robust pipeline, GRI Bio continues to drive forward in its mission to improve patient outcomes through cutting-edge science and targeted therapies.
GRI Bio (NASDAQ: GRI) recently participated in a Virtual Investor KOL Connect segment, featuring Albert Agro, PhD, CMO of GRI Bio, and Dr. Helen Parfrey, a prominent expert in Idiopathic Pulmonary Fibrosis (IPF). The discussion focused on IPF, current patient experiences, and GRI Bio's lead program, GRI-0621. This small molecule RAR-βɣ dual agonist inhibits iNKT cell activity and has shown promise in improving fibrosis and inflammation markers in preliminary trials.
GRI Bio is advancing GRI-0621 through a Phase 2a biomarker study, with interim data expected in Q4 2024 and topline data in Q1 2025. The company aims to address the limitations of current IPF treatments, which have significant side effects and impact on overall survival. GRI-0621 represents a potential new therapeutic approach to halt disease progression in fibrotic diseases like IPF.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
CEO Marc Hertz, PhD, will deliver a presentation and engage in one-on-one meetings with qualified investors. A video webcast of the presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for registered attendees. The webcast will also be accessible on the company's website and archived for 90 days post-event.
GRI Bio (NASDAQ: GRI), a biotech company developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 2024 European Respiratory Congress (ERS) in Vienna, Austria. The company's abstract has been accepted for a poster presentation on September 9, 2024.
The presentation, titled 'Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis', will be delivered by Emily Calamita from Dr. Adam Byrne's laboratory at Imperial College London. This research aligns with GRI Bio's focus on NKT cell modulators and their potential applications in treating respiratory conditions.
The poster session, scheduled from 12:30 - 2:00 PM CEST, falls under the category of 'Novel Insights in the Pathogenesis of Pulmonary Fibrosis', highlighting the company's contributions to advancing understanding in this field.
GRI Bio (NASDAQ: GRI) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) on track with interim data expected in Q4 2024 and topline data in Q1 2025.
2. Net loss of $2.4 million for Q2 2024.
3. R&D expenses at $0.9 million, G&A expenses at $1.4 million.
4. Cash and equivalents of $6.4 million as of June 30, 2024.
5. Closed a public offering with gross proceeds of $4.0 million.
6. Cash runway expected into Q1 2025.
7. Expanded IP protection with Korean patent grant.
8. Presented positive preclinical data for GRI-0621 in IPF and GRI-0803 for systemic lupus erythematosus.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the Virtual Investor Lunch Break Series on July 17, 2024, at 12:00 PM ET. The event will feature a corporate overview and business outlook presented by CEO Marc Hertz, PhD.
Investors can join the live video webcast and participate in a Q&A session. The presentation will be available on the company's website, with a replay accessible for 90 days following the event. This presentation offers an opportunity for stakeholders to gain insights into GRI Bio's innovative pipeline and future prospects.
GRI Bio (NASDAQ: GRI), a biotechnology firm specializing in NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases, has released a Virtual Investor 'What This Means' segment. CEO Marc Hertz, PhD, emphasizes the significance of interim data from their Phase 2a biomarker study on Idiopathic Pulmonary Fibrosis (IPF) for the GRI-0621 program. This segment delves into the implications of the data for GRI Bio's ongoing IPF study. The video is available for viewing on the Virtual Investor website.
GRI Bio, a biotechnology company, has regained compliance with Nasdaq listing standards as of July 2, 2024. The company, known for its Natural Killer T cell modulators targeting inflammatory, fibrotic, and autoimmune diseases, received a notice from Nasdaq indicating that it meets all requirements for continued listing on the Nasdaq Capital Market. Consequently, the scheduled hearing before the Hearings Panel has been canceled. CEO Marc Hertz expressed excitement over this development and emphasized the company's focus on advancing their core business objectives.
GRI Bio has published promising preclinical data for its lead program, GRI-0621, in the American Journal of Respiratory and Critical Care Medicine. The study shows that inhibiting type 1 invariant NKT (iNKT) cell activity can reduce fibrosis and inflammation in a mouse model of Idiopathic Pulmonary Fibrosis (IPF). Compared to controls, GRI-0621-treated mice exhibited significant improvements in lung histology, decreased fibrosis scores, and reduced lung inflammation. The company is advancing a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim results expected in Q3 2024 and topline data in Q4 2024.
GRI Bio, a biotechnology company specializing in Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, is set to present at the 8th Annual IPF Summit. The event will take place from August 20-22, 2024, in Boston, MA.
Vipin Kumar Chaturvedi, PhD, the Chief Scientific Officer of GRI Bio, will deliver a presentation titled 'Examining the Underlying Mechanism & Patients Subject to the Therapeutic Potential of NKT-Cell Targeting.' This session will be part of the 'Exploring the Clinical Promise of Emerging Modalities & Targets from NKT-Cells to ADCs, Small RNA Inhibitors, Nanotechnology for Fibrosis Control' segment scheduled for August 22, 2024, from 8:00-8:30 AM ET.
For more details, attendees are encouraged to visit the conference website.
GRI Bio announced the closing of its $4.0 million public offering. The offering included 2,185,793 shares of common stock and Series C-1 and C-2 warrants to purchase additional shares, all priced at $1.83 per share. The Series C-1 warrants expire five years from the initial exercise date, while the Series C-2 warrants expire eighteen months from the initial exercise date. H.C. Wainwright & Co. acted as the exclusive placement agent. Gross proceeds before fees and expenses were approximately $4.0 million, with potential additional gross proceeds of $8.0 million if all warrants are exercised for cash. Proceeds will be used for product development, working capital, and general corporate purposes. The offering was made via an effective registration statement on Form S-1, declared effective by the SEC on June 26, 2024.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
What does GRI Bio, Inc. specialize in?
What is GRI Bio's lead program?
How does GRI-0621 work?
What other products is GRI Bio developing?
What makes NKT cells unique?
What stage is GRI Bio in?
Who can I contact for investor-related inquiries?
What is the significance of GRI-0803?
Does GRI Bio have any partnerships?